SMAD6

Across TCGA pan-cancer cohorts, SMAD6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMAD6 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SMAD6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMAD6 expression acts as an unfavorable survival marker.

CESC, BLCA, and LUSC are the cancer types where SMAD6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.242	0.798	.003	24	view →
BLCA	OS	Median	III,IV	0.051	0.684	<.001	24	view →
LUSC	DFS	Median	II,III,IV	0.185	0.717	.012	6	view →
SKCM	OS	Median	II,III,IV	0.396	0.735	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMAD6–CESC (OS)

Open the CESC breakdown →